T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
XYZ
Block Inc
XYZ
|
+$2.39B |
| 2 |
Carvana
CVNA
|
+$1.82B |
| 3 |
Microsoft
MSFT
|
+$1.5B |
| 4 |
Walt Disney
DIS
|
+$1.25B |
| 5 |
Spotify
SPOT
|
+$1.05B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$2.65B |
| 2 |
Intuit
INTU
|
+$2.08B |
| 3 |
Match Group
MTCH
|
+$1.87B |
| 4 |
Salesforce
CRM
|
+$1.76B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.61B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.08% |
| 2 | Healthcare | 16.24% |
| 3 | Consumer Discretionary | 15.33% |
| 4 | Communication Services | 13.82% |
| 5 | Financials | 12.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1401
United Therapeutics
UTHR
$21.9B
| $11.1M | ﹤0.01% |
60,234
-1,021
| -2% | -$201K |
|
1402
Innospec
IOSP
$2.29B
| $11.1M | ﹤0.01% |
131,684
-30,962
| -19% | -$2.76M |
|
|
GTHX
1403
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $11.1M | ﹤0.01% |
823,742
-3,847
| -0.5% | -$62.7K |
|
1404
Invitation Homes
INVH
$17.7B
| $11M | ﹤0.01% |
286,654
-23,200
| -7% | -$930K |
|
1405
CVRx
CVRX
$78.3M
| $10.3M | ﹤0.01% |
622,615
+22,615
| +4% | +$434K |
|
1406
Zscaler
ZS
$28.7B
| $10.2M | ﹤0.01% |
38,967
-901
| -2% | -$226K |
|
1407
Bentley Systems
BSY
$10.8B
| $10.2M | ﹤0.01% |
167,628
+33,434
| +25% | +$2.13M |
|
|
SFIX
1408
Stitch Fix
SFIX
$474M
| $10.1M | ﹤0.01% |
252,264
+101,428
| +67% | +$4.74M |
|
|
INFN
1409
DELISTED
Infinera Corporation Common Stock
INFN
| $10M | ﹤0.01% |
1,203,562
-3,967
| -0.3% | -$36K |
|
1410
iShares Russell 1000 Growth ETF
IWF
$129B
| $10M | ﹤0.01% |
146,008
+23,940
| +20% | +$1.69M |
|
|
BNR
1411
Burning Rock Biotech
BNR
$105M
| $9.91M | ﹤0.01% |
55,448
-285
| -0.5% | -$63.4K |
|
1412
XPeng
XPEV
$11.3B
| $9.87M | ﹤0.01% |
+277,565
| New | +$11M |
|
1413
Syndax Pharmaceuticals
SNDX
$1.77B
| $9.86M | ﹤0.01% |
516,098
+95,678
| +23% | +$1.59M |
|
1414
Leggett & Platt
LEG
$1.29B
| $9.8M | ﹤0.01% |
218,525
-3,907
| -2% | -$188K |
|
1415
Solid Biosciences
SLDB
$972M
| $9.77M | ﹤0.01% |
272,557
-655
| -0.2% | -$27.8K |
|
1416
Bumble
BMBL
$344M
| $9.74M | ﹤0.01% |
194,822
-23,800
| -11% | -$1.24M |
|
1417
AtaiBeckley Inc
ATAI
$2.68B
| $9.59M | ﹤0.01% |
648,074
-1,926
| -0.3% | -$31.3K |
|
1418
Seres Therapeutics
MCRB
$47.4M
| $9.47M | ﹤0.01% |
68,026
-1,366
| -2% | -$267K |
|
1419
Oxford Industries
OXM
$538M
| $9.39M | ﹤0.01% |
104,172
+97,658
| +1,499% | +$8.89M |
|
1420
Lyft
LYFT
$6.28B
| $9.29M | ﹤0.01% |
173,444
-137,264
| -44% | -$7.28M |
|
|
MRSN
1421
DELISTED
Mersana Therapeutics
MRSN
| $9.25M | ﹤0.01% |
39,236
-53,474
| -58% | -$15.6M |
|
|
STOR
1422
DELISTED
STORE Capital Corporation
STOR
| $9.23M | ﹤0.01% |
288,123
-179,836
| -38% | -$6.37M |
|
1423
AMC Entertainment Holdings
AMC
$2.26B
| $9.23M | ﹤0.01% |
24,243
+2,391
| +11% | +$964K |
|
|
SQSP
1424
DELISTED
Squarespace, Inc.
SQSP
| $8.95M | ﹤0.01% |
231,681
-129,987
| -36% | -$6.28M |
|
|
SUMO
1425
DELISTED
Sumo Logic, Inc. Common Stock
SUMO
| $8.9M | ﹤0.01% |
+552,011
| New | +$11M |
|
Similar funds
T. Rowe Price Associates's Q3 2021 Portfolio in Review
As of Q3 2021, T. Rowe Price Associates held 3,048 positions worth $1.06T, down 1.6% from $1.08T the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q3 2021 filing shows 131 new, 1,029 increased, 1,524 reduced and 112 closed positions. Its largest new stake was Warby Parker: 17,643,113 shares worth $936M. The largest sale was Visa, an estimated $2.65B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q3 2021 buy was Warby Parker: 17,643,113 shares worth $936M.
- T. Rowe Price Associates added most to Block Inc in Q3 2021, an estimated $2.39B increase.
- T. Rowe Price Associates's biggest Q3 2021 reduction was Visa, cutting an estimated $2.65B.
- T. Rowe Price Associates fully exited Maxim Integrated Products in Q3 2021, selling an estimated $394M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $1.06T portfolio in Q3 2021.
- T. Rowe Price Associates opened 131 new positions and closed 112 in Q3 2021.
- T. Rowe Price Associates's portfolio value fell 1.6% quarter-over-quarter to $1.06T.
Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.